Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01344447
Registration number
NCT01344447
Ethics application status
Date submitted
5/04/2011
Date registered
29/04/2011
Date last updated
4/01/2019
Titles & IDs
Public title
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Query!
Scientific title
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels
Query!
Secondary ID [1]
0
0
2010-023001-36
Query!
Secondary ID [2]
0
0
14607
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
GEMSAV
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carotid Stenosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Gadobutrol (Gadovist, BAY86-4875)
Experimental: Arm 1 -
Treatment: Drugs: Gadobutrol (Gadovist, BAY86-4875)
A single bolus injection of approx. 0.1mmol/kg
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Query!
Assessment method [1]
0
0
Each vascular segment was visualized using unenhanced MRA and gadobutrol-enhanced MRA, characterized by the on-site investigators, three independent blinded readers (BR) (BR 1, BR 2 and BR 3) and majority readers (the outcome determined by at least two of the blinded readers). A segment was assessable if it was visualized along its entire length and if any region of stenosis, was measured reliably. There were 21 segments of the supra-aortic arteries assessed per participant.
Query!
Timepoint [1]
0
0
Images were taken pre-injection and post-injection
Query!
Primary outcome [2]
0
0
Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Query!
Assessment method [2]
0
0
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the standard of reference (SoR) (computed tomographic angiography [CTA]; blinded readers). This was determined using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.
Query!
Timepoint [2]
0
0
Images were taken pre-injection and post-injection
Query!
Primary outcome [3]
0
0
Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Query!
Assessment method [3]
0
0
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the SoR (CTA; blinded readers). This was determined using the NASCET criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.
Query!
Timepoint [3]
0
0
Images were taken pre-injection and post-injection
Query!
Primary outcome [4]
0
0
Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%
Query!
Assessment method [4]
0
0
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.
Query!
Timepoint [4]
0
0
Images were taken pre-injection and post-injection
Query!
Primary outcome [5]
0
0
Minimum Gadobutrol Performance for Specificity: Specificity > 50%
Query!
Assessment method [5]
0
0
Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.
Query!
Timepoint [5]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [1]
0
0
Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images
Query!
Assessment method [1]
0
0
The segment reduction in diameter (DIA) of greater than 10% was considered abnormal and measured. The diameter of each of these abnormal segments was measured using electronic calipers (perpendicular to the long axis of the vessel) at the point of most severe stenosis within each segment. Mean of vessel diameters was calculated by segment separately for CTA and MRA readers. For ease of expression, the following abbreviations will be used: Diameter (DIA), Blinded Reader (BR), Clinical Investigator (CI).
Query!
Timepoint [1]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [2]
0
0
The Percentage of Segments With Artifacts Presence
Query!
Assessment method [2]
0
0
Artifacts were collected for the MRA images on a segmental basis.
Query!
Timepoint [2]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [3]
0
0
Types of Artifacts on a Segment Basis by Blinded Reader 1
Query!
Assessment method [3]
0
0
The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example [eg], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).
Query!
Timepoint [3]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [4]
0
0
Types of Artifacts on a Segment Basis by Blinded Reader 2
Query!
Assessment method [4]
0
0
The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example [eg], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).
Query!
Timepoint [4]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [5]
0
0
Types of Artifacts on a Segment Basis by Blinded Reader 3
Query!
Assessment method [5]
0
0
The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example [eg], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).
Query!
Timepoint [5]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [6]
0
0
The Percentage of Location of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA
Query!
Assessment method [6]
0
0
Location within a segment was based on the point of greatest stenosis and was recorded for stenosis >=70% (including occlusions) as: - At the bifurcation or proximal origin of a segment (occlusion proximal to the origin of the segment); - Within 5 mm of the bifurcation or proximal origin of a segment; - Beyond 5 mm from the bifurcation or proximal origin of a segment.
Query!
Timepoint [6]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [7]
0
0
Length of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA
Query!
Assessment method [7]
0
0
The length of stenosis was based on the most proximal (first point) in a segment where a stenosis exceeded 10% and the most distal point (last point) in the segment where a stenosis exceeded 10%. If a stenosis spanned more than one segment then the measurement was only included to the beginning or end (boundary) of the segment being evaluated. If there was no stenosis of >=70% in a segment then the length was designated as 0.
Query!
Timepoint [7]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [8]
0
0
The Percentage of Presence of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease
Query!
Assessment method [8]
0
0
Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present.
Query!
Timepoint [8]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [9]
0
0
Type of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease
Query!
Assessment method [9]
0
0
Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present. If there were tandem (serial) stenosis in a vessel then the secondary signs were assigned to the stenosis of >=70% that was proximal and closest in proximity to the secondary sign.
Query!
Timepoint [9]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [10]
0
0
Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Query!
Assessment method [10]
0
0
Diagnostic confidence was evaluated to determine the level of certainty that the blinded readers assigned to a diagnosis for each segment. This was defined as the degree of confidence that the information on the MRA images represented the true and complete clinical picture of a particular segment. The degree of confidence was rated on a 4-point scale: 1 = Not confident, 2 = Somewhat confident, 3 = Confident, and 4 = Very confident.
Query!
Timepoint [10]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [11]
0
0
The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images
Query!
Assessment method [11]
0
0
A measure of diagnostic value was the reduction in the number of additional diagnostic imaging studies recommended/ordered. The clinical investigators and the blinded readers were asked if they would have recommended an additional imaging study for each participant and was recorded.
Query!
Timepoint [11]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [12]
0
0
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 1
Query!
Assessment method [12]
0
0
An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.
Query!
Timepoint [12]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [13]
0
0
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 2
Query!
Assessment method [13]
0
0
An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.
Query!
Timepoint [13]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [14]
0
0
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 3
Query!
Assessment method [14]
0
0
An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.
Query!
Timepoint [14]
0
0
Images were taken pre-injection and post-injection
Query!
Secondary outcome [15]
0
0
Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images
Query!
Assessment method [15]
0
0
An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.
Query!
Timepoint [15]
0
0
Images were taken pre-injection and post-injection
Query!
Eligibility
Key inclusion criteria
- Male or female subjects, aged 18 years and older
- Any of the following:
- Known or suspected supra-aortic arterial disease based on:
- Prior stroke
- Transient ischemic attack (TIA)
- Amaurosis Fugax (transient monocular blindness)
- Referred for evaluation of any supra-aortic vessel (for clinically significant
stenosis)
- Follow-up for a stent in a supra-aortic vessel
- Prior imaging study (CTA or ultrasound) showing = 50% stenosis of a supra-aortic
vessel segment (within 60 days before consent). The proportion of subjects with
positive disease (determined by the investigator, based on CTA or ultrasound)
will be monitored during the study, and enrolment may be further restricted to
require = 70% stenosis to ensure that overall there are an adequate number of
subjects with clinically significant disease for the evaluation of study
endpoints.
- Willingness to undergo the routine Contrast Enhanced Magnetic Resonance Angiography
[CE MRA] examination with gadobutrol
- Willingness and ability to follow directions and complete all study procedures
specified in the protocol
- Females of childbearing potential only: Negative pregnancy test on the day of the MRA
before the administration of study drug
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Pregnant or nursing (including pumping for storage and feeding)
- Received any other investigational product or participation in any other clinical
trial within 30 days before enrollment into this study
- Previous enrollment into this study or into any other Bayer sponsored study using
gadobutrol
- Contraindication to the MRA examinations (e.g. inability to hold breath; severe
arrhythmias; very low cardiac output, severe claustrophobia, defibrillators or other
metallic devices not approved for MRI)
- Contraindication to the use of Gd-containing contrast agents (including subjects with
suspicion for or known to have Nephrogenic Systemic Fibrosis [NSF])
- History of severe allergic or anaphylactoid reaction to any allergen including drugs
and contrast agents
- Received any contrast agent within 72 hours before the study MRA, or scheduled receipt
of any contrast agent within 24 hours after the study MRA (Note: This applies also to
a CTA potentially scheduled during the course of the study.)
- Estimated glomerular filtration rate (eGFR) value < 30 ml/min/1.73 m2 derived from a
serum creatinine result within 2 weeks before the gadobutrol injection. Any subject on
hemodialysis or peritoneal dialysis is excluded from participation. Use the value
obtained prior to and closest to the time of the MRA, if there are multiple creatinine
values. (Do not use the core lab value if not available prior to the MRA.)
- Acute renal insufficiency of any intensity, either due to hepato-renal syndrome or
occurring in the peri-operative liver transplantation period
- Severe cardiovascular disease (e.g. acute myocardial infarction [< 14 days], unstable
angina, congestive heart failure New York Heart Association class IV) or known long QT
syndrome
- Suspected clinical instability or unpredictability of the clinical course during the
study period (e.g. due to previous surgery)
- Scheduled or potentially expected for the period between the CTA and gadobutrol MRA:
- Any procedure that may alter the MRA or CTA interpretation, or
- Any interventional or surgical procedure involving the supra-aortic vessels
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/05/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
28/05/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
479
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
- New Lambton Heights
Query!
Recruitment hospital [2]
0
0
- Clayton
Query!
Recruitment hospital [3]
0
0
- Parkville
Query!
Recruitment postcode(s) [1]
0
0
2305 - New Lambton Heights
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3052 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kentucky
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Mississippi
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Rhode Island
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Washington
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Wisconsin
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Ciudad Auton. De Buenos Aires
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Tirol
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Wien
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Shanghai
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Brno
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Brest Cedex
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
BRON Cedex
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Marseille
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Paris Cedex 15
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Baden-Württemberg
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Bayern
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Nordrhein-Westfalen
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Thüringen
Query!
Country [30]
0
0
Italy
Query!
State/province [30]
0
0
Emilia-Romagna
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Lazio
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Sicilia
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Toscana
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Valle d'Aosta
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Veneto
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Gwangju Gwang''yeogsi
Query!
Country [37]
0
0
Korea, Republic of
Query!
State/province [37]
0
0
Seoul
Query!
Country [38]
0
0
Poland
Query!
State/province [38]
0
0
Bydgoszcz
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Lodz
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Warszawa
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Wroclaw
Query!
Country [42]
0
0
Sweden
Query!
State/province [42]
0
0
Linköping
Query!
Country [43]
0
0
Sweden
Query!
State/province [43]
0
0
Uppsala
Query!
Country [44]
0
0
Switzerland
Query!
State/province [44]
0
0
Sankt Gallen
Query!
Country [45]
0
0
Turkey
Query!
State/province [45]
0
0
Antalya
Query!
Country [46]
0
0
Turkey
Query!
State/province [46]
0
0
Erzurum
Query!
Country [47]
0
0
Turkey
Query!
State/province [47]
0
0
Istanbul
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic
resonance angiography) will be invited to participate in the study and subjects will be
involved in the study for between 2 and 12 days. Two to three visits to the study doctor will
be required.
This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA
images taken without contrast agent using images from a CTA as the standard of reference,
which may have been performed up to 60 days prior to enrolment. If a CTA has not been
performed in this prior time period, a CTA is required for the study.
MRA and CTA images will be collected for an independent review (blinded read).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01344447
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01344447
Download to PDF